Clinical Insights in Myelofibrosis: Addressing Unmet Needs & Advancing Outcomes

Panelists discuss optimizing treatment strategies for higher-risk myelofibrosis patients. They focus on managing thrombocytopenia, anemia, and ruxolitinib failure while exploring the role of JAK inhibitors and sequencing therapies.

EP. 1: Clinical Perspectives: Firstline Treatment Landscape in Higher-Risk MF

November 27th 2024

Panelists discuss how frequently patients with newly diagnosed myelofibrosis present with moderate or severe thrombocytopenia or both anemia and thrombocytopenia. They discuss how these factors and other disease characteristics like spleen size and constitutional symptoms influence their treatment approach and selection of JAK inhibitors.

EP. 2: Tackling Complex Clinical Scenarios: MF Patients With Thrombocytopenia and Anemia

December 4th 2024

Panelists discuss the latest data on pacritinib’s effects on anemia and bicytopenia, and share their treatment approaches for patients with myelofibrosis who present with both thrombocytopenia and anemia.

EP. 3: Challenges With Defining “Ruxolitinib Failure” or Suboptimal Response to Ruxolitinib in MF

December 11th 2024

Panelists discuss how they define “ruxolitinib failure” and a suboptimal response, when they consider switching from first-line ruxolitinib, and how they differentiate between myelofibrosis-induced and JAK-induced cytopenias.

EP. 4: Clinical Insights on Managing Ruxolitinib Cytopenias: Patient-Focused Approach

December 18th 2024

Panelists discuss the patient and disease characteristics influencing the decision to dose-reduce ruxolitinib vs switching therapy. They share their typical sequencing approach after first-line ruxolitinib, including whether a washout period or overlap is required.